Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2018

01.10.2018 | Research Article

Perceptions, opinions and knowledge of pharmacists towards the use of complementary medicines by people living with cancer

verfasst von: Joanna Harnett, Trong Quy Le, Lorraine Smith, Ines Krass

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background Biologically-based complementary medicine (BB-CM) use is prevalent amongst people living with cancer. Pharmacists play an important role in the provision of standard treatments for cancer. Less is known about pharmacist’s provision of BB-CM information. Objective This study investigated the opinions, perceptions and knowledge of pharmacists regarding the use of BB-CMs by people living with cancer and the facilitators and barriers to providing information and advice. Setting Australia. Method A cross-sectional 53-item survey was developed and the survey link distributed in two professional associations newsletters. The associations represent ~29,000 pharmacists. Questions were categories into pharmacist’s perceptions, opinions, and knowledge towards the use of BB-CM in cancer. Main Outcome Measure Scores obtained from responses to perception, opinion and knowledge statements and responses to demographic questions Results Respondents (n=70) were predominantly female (73%), Caucasian (66%) and under 40 years of age (78%). Respondents estimated that 19% of daily inquiries related to BB-CMs. Seventy-two per cent of respondents believed they had a responsibility to advise about the concomitant use of BB-CM with standard cancer treatments despite 60% reporting a lack of confidence in their knowledge. There was a moderate positive association (Spearman’s rho 0.41 p= 0.001) between a pharmacists confidence in their level of knowledge and their total knowledge scores. The main barriers to providing information about BB-CMs reported were inadequate training in BB-CMs (94%) and reservations about the evidence base for efficacy and safety (50%). Conclusion Pharmacists have a role to play in counselling people living with cancer about their use of BB-CMs and this role could be maximized with further training and education in this area.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement–drug interactions: a systematic review. Phytother Res. 2014;28(12):1749–55.CrossRef Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement–drug interactions: a systematic review. Phytother Res. 2014;28(12):1749–55.CrossRef
2.
Zurück zum Zitat Ernst E. The prevalence of complementary/alternative medicine in cancer. Cancer. 1998;83(4):777–82.CrossRef Ernst E. The prevalence of complementary/alternative medicine in cancer. Cancer. 1998;83(4):777–82.CrossRef
3.
Zurück zum Zitat Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.CrossRef Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.CrossRef
4.
Zurück zum Zitat Braun L, Tiralongo E, Wilkinson J, Spitzer O, Bailey M, Poole S, et al. Perceptions, use and attitudes of pharmacy customers on complementary medicines and pharmacy practice. BMC Complement Altern Med. 2010;10:38.CrossRef Braun L, Tiralongo E, Wilkinson J, Spitzer O, Bailey M, Poole S, et al. Perceptions, use and attitudes of pharmacy customers on complementary medicines and pharmacy practice. BMC Complement Altern Med. 2010;10:38.CrossRef
5.
Zurück zum Zitat Braun L, Harris J, Katris P, Cain M, Dhillon H, Koczwara B, et al. Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia Pac J Clin Oncol. 2014;10(4):289–96.CrossRef Braun L, Harris J, Katris P, Cain M, Dhillon H, Koczwara B, et al. Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia Pac J Clin Oncol. 2014;10(4):289–96.CrossRef
6.
Zurück zum Zitat Templeman K, Robinson A, McKenna L. Student identification of the need for complementary medicine education in Australian medical curricula: a constructivist grounded theory approach. Complement Ther Med. 2015;23(2):257–64.CrossRef Templeman K, Robinson A, McKenna L. Student identification of the need for complementary medicine education in Australian medical curricula: a constructivist grounded theory approach. Complement Ther Med. 2015;23(2):257–64.CrossRef
8.
Zurück zum Zitat Tiralongo E, Wallis M. Attitudes and perceptions of Australian pharmacy students towards complementary and alternative medicine—a pilot study. BMC Complement Altern Med. 2008;8:2.CrossRef Tiralongo E, Wallis M. Attitudes and perceptions of Australian pharmacy students towards complementary and alternative medicine—a pilot study. BMC Complement Altern Med. 2008;8:2.CrossRef
9.
Zurück zum Zitat Tiralongo E, Wallis M. Integrating complementary and alternative medicine education into the pharmacy curriculum. Am J Pharm Educ. 2008;72(4):74.CrossRef Tiralongo E, Wallis M. Integrating complementary and alternative medicine education into the pharmacy curriculum. Am J Pharm Educ. 2008;72(4):74.CrossRef
10.
Zurück zum Zitat Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 2012;25(4):213–23.CrossRef Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 2012;25(4):213–23.CrossRef
11.
Zurück zum Zitat Ung COL, Harnett J, Hu H. Key stakeholder perspectives on the barriers and solutions to pharmacy practice towards complementary medicines: an Australian experience. BMC Complement Altern Med. 2017;17(1):394.CrossRef Ung COL, Harnett J, Hu H. Key stakeholder perspectives on the barriers and solutions to pharmacy practice towards complementary medicines: an Australian experience. BMC Complement Altern Med. 2017;17(1):394.CrossRef
12.
Zurück zum Zitat Le TQ, Smith L, Harnett J. A systematic review: biologically-based complementary medicine use by people living with cancer—is a more clearly defined role for the pharmacist required? Res Soc Adm Pharm. 2017;13:1037–44.CrossRef Le TQ, Smith L, Harnett J. A systematic review: biologically-based complementary medicine use by people living with cancer—is a more clearly defined role for the pharmacist required? Res Soc Adm Pharm. 2017;13:1037–44.CrossRef
14.
Zurück zum Zitat Culverhouse S, Wohlmuth H. Factors affecting pharmacists’ recommendation of complementary medicines—a qualitative pilot study of Australian pharmacists. BMC Complement Altern Med. 2012;12(1):183.CrossRef Culverhouse S, Wohlmuth H. Factors affecting pharmacists’ recommendation of complementary medicines—a qualitative pilot study of Australian pharmacists. BMC Complement Altern Med. 2012;12(1):183.CrossRef
15.
Zurück zum Zitat Morgan TK. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196(1):50–3.CrossRef Morgan TK. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196(1):50–3.CrossRef
16.
Zurück zum Zitat Hunter D, Oates R, Gawthrop J, Bishop M, Gill S. Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients. Support Care Cancer. 2014;22(6):1571–8.CrossRef Hunter D, Oates R, Gawthrop J, Bishop M, Gill S. Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients. Support Care Cancer. 2014;22(6):1571–8.CrossRef
17.
Zurück zum Zitat Braun L, Spitzer O, Tiralongo E, Wilkinson J, Bailey M, Poole S, et al. The prevalence and experience of Australian naturopaths and Western herbalists working within community pharmacies. BMC Complement Altern Med. 2011;11:41.CrossRef Braun L, Spitzer O, Tiralongo E, Wilkinson J, Bailey M, Poole S, et al. The prevalence and experience of Australian naturopaths and Western herbalists working within community pharmacies. BMC Complement Altern Med. 2011;11:41.CrossRef
19.
Zurück zum Zitat Kerridge IH, McPhee JR. Ethical and legal issues at the interface of complementary and conventional medicine. Med J Aust. 2004;181(3):164–6.PubMed Kerridge IH, McPhee JR. Ethical and legal issues at the interface of complementary and conventional medicine. Med J Aust. 2004;181(3):164–6.PubMed
20.
Zurück zum Zitat Kheir N, Gad HY, Abu-Yousef SE. Pharmacists’ knowledge and attitudes about natural health products: a mixed-methods study. Drug Healthc Patient Saf. 2014;6:7.CrossRef Kheir N, Gad HY, Abu-Yousef SE. Pharmacists’ knowledge and attitudes about natural health products: a mixed-methods study. Drug Healthc Patient Saf. 2014;6:7.CrossRef
21.
Zurück zum Zitat Sullivan A, Gilbar P, Curtain C. Complementary and alternative medicine use in cancer patients in rural Australia. Integr Cancer Ther. 2015;14(4):350–8.CrossRef Sullivan A, Gilbar P, Curtain C. Complementary and alternative medicine use in cancer patients in rural Australia. Integr Cancer Ther. 2015;14(4):350–8.CrossRef
22.
Zurück zum Zitat Du M, Yang X, Hartman JA, Cooke PS, Doerge DR, Ju YH, et al. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis. 2012;33:895–901.CrossRef Du M, Yang X, Hartman JA, Cooke PS, Doerge DR, Ju YH, et al. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis. 2012;33:895–901.CrossRef
23.
Zurück zum Zitat Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005;65(3):879–86.PubMed Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005;65(3):879–86.PubMed
24.
Zurück zum Zitat Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Exp Opin Drug Metabol Toxicol. 2014;10(3):359–77.CrossRef Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Exp Opin Drug Metabol Toxicol. 2014;10(3):359–77.CrossRef
25.
Zurück zum Zitat El Haouari M, Rosado JA. Medicinal plants with antiplatelet activity. Phytother Res. 2016;30(7):1059–71.CrossRef El Haouari M, Rosado JA. Medicinal plants with antiplatelet activity. Phytother Res. 2016;30(7):1059–71.CrossRef
26.
Zurück zum Zitat Brown AC. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 6. Food Chem Toxicol. 2016;107:502–19.CrossRef Brown AC. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 6. Food Chem Toxicol. 2016;107:502–19.CrossRef
27.
Zurück zum Zitat Marx W, McCarthy AL, Ried K, McKavanagh D, Vitetta L, Sali A, et al. The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial. Nutrients. 2017;9(8):867.CrossRef Marx W, McCarthy AL, Ried K, McKavanagh D, Vitetta L, Sali A, et al. The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial. Nutrients. 2017;9(8):867.CrossRef
28.
Zurück zum Zitat Conklin KA. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005;4(2):110–30.CrossRef Conklin KA. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005;4(2):110–30.CrossRef
29.
Zurück zum Zitat Swarnakar NK, Thanki K, Jain S. Enhanced antitumor efficacy and counterfeited cardiotoxicity of combinatorial oral therapy using doxorubicin- and coenzyme Q10-liquid crystalline nanoparticles in comparison with intravenous Adriamycin. Nanomedicine. 2014;10(6):1231–41.CrossRef Swarnakar NK, Thanki K, Jain S. Enhanced antitumor efficacy and counterfeited cardiotoxicity of combinatorial oral therapy using doxorubicin- and coenzyme Q10-liquid crystalline nanoparticles in comparison with intravenous Adriamycin. Nanomedicine. 2014;10(6):1231–41.CrossRef
30.
Zurück zum Zitat Chen PY, Hou CW, Shibu MA, Day CH, Pai P, Liu ZR, et al. Protective effect of co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. Environ Toxicol. 2017;32(2):679–89.CrossRef Chen PY, Hou CW, Shibu MA, Day CH, Pai P, Liu ZR, et al. Protective effect of co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. Environ Toxicol. 2017;32(2):679–89.CrossRef
31.
Zurück zum Zitat Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep. 1978;62(6):887–91.PubMed Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep. 1978;62(6):887–91.PubMed
32.
Zurück zum Zitat Tsubaki K, Horiuchi A, Kitani T, Taniguchi N, Masaoka T, Shibata H, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan to kagaku ryoho Cancer Chemother. 1984;11(7):1420–7. Tsubaki K, Horiuchi A, Kitani T, Taniguchi N, Masaoka T, Shibata H, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan to kagaku ryoho Cancer Chemother. 1984;11(7):1420–7.
33.
Zurück zum Zitat Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15(Suppl):s207–12.CrossRef Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15(Suppl):s207–12.CrossRef
Metadaten
Titel
Perceptions, opinions and knowledge of pharmacists towards the use of complementary medicines by people living with cancer
verfasst von
Joanna Harnett
Trong Quy Le
Lorraine Smith
Ines Krass
Publikationsdatum
01.10.2018
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2018
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0645-5

Weitere Artikel der Ausgabe 5/2018

International Journal of Clinical Pharmacy 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.